The ruling blocks Lupin and Zydus Life from selling their generic version of Mirabegron, the bioequivalent of Astellas' overactive bladder drug, Myrbetriq, in the United States. According to the ...

Shares of Lupin and Zydus Life are sharply lower by 3-4.5 percent on April 16 after losing a US Federal Court patent case involving Myrbetriq - a prescription medicine used in treating overactive ...